Survey for Allergology Inhale Allergens, AL1

EQA Provider: ESfEQA GmbH Heidelberg

ESfEQA Head of Operations: Dr. D. Groche

Instructions for Use

Notes:

The samples should be considered as potentially infectious. The usual precautions in the laboratory for potential hazardous samples apply for these samples. The blood donations used for production were found to be non-reactive for HBsAg, anti-HIV 1/2 and anti-HCV. The samples should be used by trained personnel only.

WARNING: Contains methylisothiazolones.
H317 May cause allergic skin reaction.

This product contains human source material and should be considered as potentially infectious.

Various tasks of the proficiency testing scheme may occasionally be given over to qualified subcontractors. However, ESfEQA is responsible to the participants for the subcontractor's work.

1. Intended Use

The samples are intended for use as quantitative control material for External Quality Assessment (EQA) in medical laboratories for the following analytes:

1) IgE total

2) Specific IgE antibodies against:

d70	Acarus Siro
e1	Cat Epithelia
e3	Horse Eptihelia
e82	Rabbit Epithelia
k82	Latex
t2	Alder
t4	Hazel
w7	Maguerite/Ox Eye Daisy
w9	Buckhorn Plantain
w20	Nettle

2. Product Description

Sample 1: AL1_2017_02_a
Sample 2: AL1_2017_02_b

The samples are liquid, ready-to-use.

3. Storage and Stability

The samples should be stored upright at 2-8 °C. They are stable at least until the deadline for data submission as indicated below.

4. Sample Preparation and Analysis

Allow the sample to equilibrate to room temperature for 15 minutes prior to testing. Directly before use, agitate the sample by gently inverting the vial several times.

All samples should not be treated prior to the analysis with any CCD (cross-reaction carbohydrate determinant) blocking solution. Samples should be analyzed in accordance with the instructions of the instrument and reagent manufacturer.

5. Dates and Submission of Test Results

Testing Period for Sample 1 and 2: 02/10/17 – 23/10/17

Please submit your results electronically to ESfEQA at https://teqa.esfeqa.eu.

Contact your local distributor of ESfEQA programs or ESfEQA directly if you need assistance with registration in TEQA. Alternatively, though not preferred, use the fax form provided on the ESfEQA website. In both cases indicate the instrument and method used for the analysis of the samples.

A quantitative result should be reported for IgE total.

A concentration range (e.g. in kU/l) should be reported for specific IgE antibodies. Please use the following assignment for result submission:

Specific IgE concentration (kU/l)	class
< 0,35	0
0,35 – 0,7	1
0,7 – 3,5	2
3,5 – 17,5	3
17,5 - 50	4
50 – 100	5
> 100	6

6. Deadline for Data Submission

Deadline for data submission (time zone GMT +1):

Sample 1 and 2: 23/10/17

7. Data Evaluation and Reports

The individual laboratory reports can be retrieved online at https://teqa.esfeqa.eu. The reports will be available within 3 weeks after the deadline of data submission.

ESfEQA GmbH
Siemensstr. 38
69123 Heidelberg
Germany

Phone: + 49 6221 894669-70
Fax: + 49 6221 894669-90
info@esfeqa.eu
www.esfeqa.eu